- Home
- VINP vs KROS Comparison
VINP vs KROS Comparison
Compare VINP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- KROS
- Stock Information
- Founded
- VINP 2009
- KROS 2015
- Country
- VINP Brazil
- KROS United States
- Employees
- VINP N/A
- KROS N/A
- Industry
- VINP Investment Managers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- KROS Health Care
- Exchange
- VINP Nasdaq
- KROS Nasdaq
- Market Cap
- VINP 593.2M
- KROS 558.9M
- IPO Year
- VINP 2021
- KROS 2020
- Fundamental
- Price
- VINP $9.77
- KROS $13.45
- Analyst Decision
- VINP Strong Buy
- KROS Buy
- Analyst Count
- VINP 2
- KROS 13
- Target Price
- VINP $13.25
- KROS $20.63
- AVG Volume (30 Days)
- VINP 55.8K
- KROS 603.2K
- Earning Date
- VINP 08-06-2025
- KROS 08-06-2025
- Dividend Yield
- VINP 6.65%
- KROS N/A
- EPS Growth
- VINP N/A
- KROS N/A
- EPS
- VINP 0.38
- KROS 0.11
- Revenue
- VINP $126,696,258.00
- KROS $214,713,000.00
- Revenue This Year
- VINP $70.28
- KROS $5,006.76
- Revenue Next Year
- VINP $14.37
- KROS N/A
- P/E Ratio
- VINP $25.66
- KROS $123.44
- Revenue Growth
- VINP 57.51
- KROS 91657.70
- 52 Week Low
- VINP $8.66
- KROS $9.12
- 52 Week High
- VINP $11.62
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- VINP 54.87
- KROS 45.45
- Support Level
- VINP $9.43
- KROS $13.24
- Resistance Level
- VINP $9.94
- KROS $13.77
- Average True Range (ATR)
- VINP 0.25
- KROS 0.37
- MACD
- VINP 0.03
- KROS -0.04
- Stochastic Oscillator
- VINP 70.65
- KROS 38.67
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.